Ischemic mitral insufficiency
Conditions
Interventions
control group:coronary artery bypass grafting
experimental group:coronary artery bypass grafting +MVP
Sponsors
Beijing Institute of Heart Lung and Blood Vessel Disease
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients who have symptoms and confirmed coronary artery disease with left main artery disease, three-vessel disease, and proximal anterior descending artery disease who are scheduled to undergo coronary artery bypass grafting; (2) Echocardiographic diagnosis of moderate mitral valve Criteria for insufficiency: it can be diagnosed if any two of the following criteria are met (effective mitral regurgitation orifice area: 0.2-0.4 cm2, regurgitant beam width: 3-7mm, mitral regurgitation area and left atrium area The ratio is 20%-40%); (3) Aged 18-75 years.
Exclusion criteria
Exclusion criteria: (1) Mitral valve structure disease (valve leaf calcification, adhesion, perforation, prolapse, mucoid change, annulus calcification, subvalvular structure calcification, adhesion, contracture, lengthy); (2) Transthoracic echocardiography is not available Effective regurgitation orifice and left ventricular end-systolic volume index; (3) Combined with other cardiac operations; (4) Past mitral valve surgery history; (5) Cardiopulmonary bypass contraindications; (6) Cardiogenic shock at the time of admission (7) Two weeks before the patients admission, the patient has long-term intravenous use of inotropic drugs; (8) The patient has ST-segment elevation myocardial infarction that requires intervention within 7 days before admission; (9) With advanced malignant tumors, The expected survival time is less than 1 year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resting myocardial perfusion imaging;Myocardial survival of mitral valve papillary muscle-ventricular wall complex;Left ventricular end systolic volume index; | — |
Secondary
| Measure | Time frame |
|---|---|
| All cause death;Stroke;Reoperation of mitral valve;Readmission for heart failure;NYHA cardiac function increased by 1-2 grades;Increased mitral regurgitation;Other serious adverse events; | — |
Countries
China
Contacts
Public ContactYongqiang Lai
Beijing Institute of Heart Lung and Blood Vessel Disease
Outcome results
None listed